Judges - Partial List Below
Robert A. Beardsley, PhD
Executive Chair, Galera Therapeutics, Inc.
Dr. Beardsley is Executive Chair and founder of Galera Therapeutics, Inc. as well as Chair of Euclises, Inc. and Epigenetx, LLC, all three therapeutic discovery and development companies active in the oncology space. Prior to Galera, he served as CEO at Metabolic Solutions Development Corporation and Kereos, as acting CEO at Metaphore Pharmaceuticals, and in a variety of roles at Confluence Life Sciences, SImile Investors, bioStrategies Group and Vector Securities International. As part of his work with these companies he has both raised over $100M in venture and private equity funding, and played key roles in taking several candidates into the clinic. Dr. Beardsley has served on the boards of a number of other public and private life science firms, including Collagenex Pharmaceuticals, BioSeek and KemPharm.. He has an M.B.A. in Finance from the University of Chicago and a Ph.D. in Biochemical Engineering from the University of Iowa.
Executive Chair, Galera Therapeutics, Inc.
Dr. Beardsley is Executive Chair and founder of Galera Therapeutics, Inc. as well as Chair of Euclises, Inc. and Epigenetx, LLC, all three therapeutic discovery and development companies active in the oncology space. Prior to Galera, he served as CEO at Metabolic Solutions Development Corporation and Kereos, as acting CEO at Metaphore Pharmaceuticals, and in a variety of roles at Confluence Life Sciences, SImile Investors, bioStrategies Group and Vector Securities International. As part of his work with these companies he has both raised over $100M in venture and private equity funding, and played key roles in taking several candidates into the clinic. Dr. Beardsley has served on the boards of a number of other public and private life science firms, including Collagenex Pharmaceuticals, BioSeek and KemPharm.. He has an M.B.A. in Finance from the University of Chicago and a Ph.D. in Biochemical Engineering from the University of Iowa.
Robert Berg
Senior Vice President and Principal, IRI
Robert is currently a senior vice president and principal at IRI, a global market information company. Robert is responsible for commercializing three new consumer and shopper marketing solutions for consumer packaged goods (CPG) and retail companies. Robert has more than 30 years of experience in the CPG and retail/foodservice industries. Prior to IRI, he worked in the Strategy Group of IBM, PwC Consulting and Coopers & Lybrand Consulting focusing on post merger integration where he learned firsthand how to integrate and improve processes, data, technology and other resources that CPG and Retail companies deploy to inform Sales, Marketing, Supply Chain, and Finance. Prior to consulting, Robert launched three companies and consulted on the start-up of 20+ more. Robert has served as a Consultant for the Wharton Small Business Development Center and has written a review of 3 Business Incubators in West Philadelphia. Robert has an MBA from the Wharton School of the University of Pennsylvania and an AB from the University of Michigan.
Senior Vice President and Principal, IRI
Robert is currently a senior vice president and principal at IRI, a global market information company. Robert is responsible for commercializing three new consumer and shopper marketing solutions for consumer packaged goods (CPG) and retail companies. Robert has more than 30 years of experience in the CPG and retail/foodservice industries. Prior to IRI, he worked in the Strategy Group of IBM, PwC Consulting and Coopers & Lybrand Consulting focusing on post merger integration where he learned firsthand how to integrate and improve processes, data, technology and other resources that CPG and Retail companies deploy to inform Sales, Marketing, Supply Chain, and Finance. Prior to consulting, Robert launched three companies and consulted on the start-up of 20+ more. Robert has served as a Consultant for the Wharton Small Business Development Center and has written a review of 3 Business Incubators in West Philadelphia. Robert has an MBA from the Wharton School of the University of Pennsylvania and an AB from the University of Michigan.
Katherine Bowdish
Vice President, R&D and Head of Sunrise, Sanofi
Katherine Bowdish, Ph.D. recently joined Sanofi as Vice President R&D and Head of Sunrise, a new organization within Sanofi created to drive innovative research and complement Sanofi’s Global R&D strategy. Katherine was previously President & CSO of Permeon Biologics, a Flagship VentureLabs Company developing a novel Intraphilinä Technology Platform that enables intracellular biological therapies based on rationally engineered as well as naturally occurring human supercharged proteins. Prior to taking the helm at Permeon, Katherine co-founded and served as President & CEO of Anaphore (now RuiYi), a platform-based drug development company with a focus on trivalent biological therapies. Prior to this, Katherine was President of Alexion Antibody Technologies, Inc. and Senior Vice President of Alexion Pharmaceuticals upon leading the acquisition of Prolifaron by Alexion. Dr. Bowdish was the founder, CEO & CSO of Prolifaron, a privately held antibody discovery company. Dr. Bowdish previously worked with Richard A. Lerner, M.D. at The Scripps Research Institute on catalytic antibodies and related antibody technologies, and at Monsanto in agricultural biotechnology. She received her Ph.D. from Columbia University College of Physicians and Surgeons and B.S. from the College of William and Mary.
Vice President, R&D and Head of Sunrise, Sanofi
Katherine Bowdish, Ph.D. recently joined Sanofi as Vice President R&D and Head of Sunrise, a new organization within Sanofi created to drive innovative research and complement Sanofi’s Global R&D strategy. Katherine was previously President & CSO of Permeon Biologics, a Flagship VentureLabs Company developing a novel Intraphilinä Technology Platform that enables intracellular biological therapies based on rationally engineered as well as naturally occurring human supercharged proteins. Prior to taking the helm at Permeon, Katherine co-founded and served as President & CEO of Anaphore (now RuiYi), a platform-based drug development company with a focus on trivalent biological therapies. Prior to this, Katherine was President of Alexion Antibody Technologies, Inc. and Senior Vice President of Alexion Pharmaceuticals upon leading the acquisition of Prolifaron by Alexion. Dr. Bowdish was the founder, CEO & CSO of Prolifaron, a privately held antibody discovery company. Dr. Bowdish previously worked with Richard A. Lerner, M.D. at The Scripps Research Institute on catalytic antibodies and related antibody technologies, and at Monsanto in agricultural biotechnology. She received her Ph.D. from Columbia University College of Physicians and Surgeons and B.S. from the College of William and Mary.
Kapil Dhingra, MBBS
Managing Member, KAPital Consulting
Kapil Dhingra, MBBS, is Managing Member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies and investors. From 1999̵-2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc., including Vice President, Head, Oncology Disease Biology Leadership team; and Head, Oncology Clinical Development. He joined Roche from Eli Lilly, where he worked as Senior Clinical Research Physician.
Before joining industry and during his tenures at both Eli Lilly and Hoffmann-La Roche, Dr. Dhingra maintained an active academic career first as an Assistant Professor at M.D. Anderson Cancer Center, then as a Clinical Associate Professor at Indiana University School of Medicine and, most recently, as a Clinical Affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra has served on the Boards of several public and private biotechnology companies that have had successful exits and is currently a member of the Boards of several life science companies. He also serves on the NeXT panel of the NCI as well as the Commercialization Review Committee of CPRIT.
Managing Member, KAPital Consulting
Kapil Dhingra, MBBS, is Managing Member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies and investors. From 1999̵-2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc., including Vice President, Head, Oncology Disease Biology Leadership team; and Head, Oncology Clinical Development. He joined Roche from Eli Lilly, where he worked as Senior Clinical Research Physician.
Before joining industry and during his tenures at both Eli Lilly and Hoffmann-La Roche, Dr. Dhingra maintained an active academic career first as an Assistant Professor at M.D. Anderson Cancer Center, then as a Clinical Associate Professor at Indiana University School of Medicine and, most recently, as a Clinical Affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra has served on the Boards of several public and private biotechnology companies that have had successful exits and is currently a member of the Boards of several life science companies. He also serves on the NeXT panel of the NCI as well as the Commercialization Review Committee of CPRIT.
Nick Donofrio
IBM Fellow Emeritus
IBM Executive Vice President, Innovation and Technology (Retired)
Nick Donofrio is a 44-year IBM veteran who led IBM’s technology and innovation strategies from 1997 until his retirement in October 2008. He also was vice chairman of the IBM International Foundation and chairman of the Board of Governors for the IBM Academy of Technology. Mr. Donofrio's most recent responsibilities included IBM Research, Governmental Programs, Technical Support & Quality, Corporate Community Relations, as well as Environmental Health & Product Safety. Also reporting to Mr. Donofrio were the senior executives responsible for IBM's enterprise on demand transformation. In addition to that strategic business mission, Mr. Donofrio led the development and retention of IBM's technical population and enriched that community with a diversity of culture and thought. In 2008 IBM Chairman Sam Palmisano elected Nick IBM Fellow, the company’s highest technical honor
Mr. Donofrio joined IBM as a college co-op student in 1964 and worked on the memory technology for the legendary IBM System/360 mainframe computing system. After being hired full time at IBM in 1967, he spent the early part of his career in integrated circuit and chip development as a designer of logic and memory chips. He held numerous technical management positions and, later, executive positions in several of IBM's product divisions. He has led many of IBM's major development and manufacturing teams – from semiconductor and storage technologies, to microprocessors and personal computers, to IBM's entire family of servers
He earned a Bachelor of Science degree in Electrical Engineering from Rensselaer Polytechnic Institute in 1967 and a Master of Science in the same discipline from Syracuse University in 1971. In 1999 he was awarded an honorary doctorate in Engineering from Polytechnic University, in 2002 he received an honorary doctorate in Sciences from the University of Warwick in England, in 2005 he was awarded an honorary doctorate in Technology from Marist College and in 2006 he received an honorary doctorate in Sciences from the University of Edinburgh in Scotland. Pace University awarded him an honorary doctorate in Sciences in 2009, the National University of Ireland, Maynooth awarded him an honorary doctorate in Sciences in 2010 and Syracuse University awarded him an honorary doctorate in Sciences in 2011
Mr. Donofrio is focused sharply on advancing education, employment and career opportunities for underrepresented minorities and women. He served for many years on the Board of Directors for the National Action Council for Minorities in Engineering (NACME) and was NACME's Board chair from 1997 through 2002. He also served for several years on the Board of Directors for INROADS, a non-profit organization focused on the training and development of talented minority youth for professional careers in business and industry. He presently is co-chair of the New York Hall of Science
In 2005, Mr. Donofrio was appointed by the U.S. Department of Education to serve on the Commission on the Future of Higher Education, a 20-member delegation of business and university leaders charged with developing a new national strategy for post-secondary education that will meet the needs of Americas diverse population and also address the economic and workforce needs of the country's future
He is the holder of seven technology patents and is a member of numerous technical and science honor societies. He is a Fellow of the Institute for Electrical and Electronics Engineers, a Fellow of the U.K-based Royal Academy of Engineering, a member of the US-based National Academy of Engineering, a Fellow of the American Academy of Arts and Sciences, a member of the Board of Directors for the Bank of New York/Mellon, a member of the Republic of China’s Science and Technology Advisory Group Board (2008-2011), a member of the Board of Trustees at Rensselaer Polytechnic Institute, a member of the Board of Directors of Liberty Mutual, a member of the Board of Directors of AMD, a member of the Board of Directors of the Delphi Company, a member of the Board of Trustees of The MITRE Corporation and a Senior Fellow of the Kauffman Foundation. In 2010, Mr. Donofrio became a member of the U. S. Secretary of Energy’s Advisory Board (SEAB), the Penn State School of International Affairs External Advisory Board and the Workforce Opportunity Services Academic Advisory Board. In 2011, he became a member of the Atlas Research Board of Advisors, Sproxil’s Board of Directors, the Syracuse University Board of Trustees and was named to the Board of Regents for Higher Education by the Governor of Connecticut
Please click here for more information
IBM Fellow Emeritus
IBM Executive Vice President, Innovation and Technology (Retired)
Nick Donofrio is a 44-year IBM veteran who led IBM’s technology and innovation strategies from 1997 until his retirement in October 2008. He also was vice chairman of the IBM International Foundation and chairman of the Board of Governors for the IBM Academy of Technology. Mr. Donofrio's most recent responsibilities included IBM Research, Governmental Programs, Technical Support & Quality, Corporate Community Relations, as well as Environmental Health & Product Safety. Also reporting to Mr. Donofrio were the senior executives responsible for IBM's enterprise on demand transformation. In addition to that strategic business mission, Mr. Donofrio led the development and retention of IBM's technical population and enriched that community with a diversity of culture and thought. In 2008 IBM Chairman Sam Palmisano elected Nick IBM Fellow, the company’s highest technical honor
Mr. Donofrio joined IBM as a college co-op student in 1964 and worked on the memory technology for the legendary IBM System/360 mainframe computing system. After being hired full time at IBM in 1967, he spent the early part of his career in integrated circuit and chip development as a designer of logic and memory chips. He held numerous technical management positions and, later, executive positions in several of IBM's product divisions. He has led many of IBM's major development and manufacturing teams – from semiconductor and storage technologies, to microprocessors and personal computers, to IBM's entire family of servers
He earned a Bachelor of Science degree in Electrical Engineering from Rensselaer Polytechnic Institute in 1967 and a Master of Science in the same discipline from Syracuse University in 1971. In 1999 he was awarded an honorary doctorate in Engineering from Polytechnic University, in 2002 he received an honorary doctorate in Sciences from the University of Warwick in England, in 2005 he was awarded an honorary doctorate in Technology from Marist College and in 2006 he received an honorary doctorate in Sciences from the University of Edinburgh in Scotland. Pace University awarded him an honorary doctorate in Sciences in 2009, the National University of Ireland, Maynooth awarded him an honorary doctorate in Sciences in 2010 and Syracuse University awarded him an honorary doctorate in Sciences in 2011
Mr. Donofrio is focused sharply on advancing education, employment and career opportunities for underrepresented minorities and women. He served for many years on the Board of Directors for the National Action Council for Minorities in Engineering (NACME) and was NACME's Board chair from 1997 through 2002. He also served for several years on the Board of Directors for INROADS, a non-profit organization focused on the training and development of talented minority youth for professional careers in business and industry. He presently is co-chair of the New York Hall of Science
In 2005, Mr. Donofrio was appointed by the U.S. Department of Education to serve on the Commission on the Future of Higher Education, a 20-member delegation of business and university leaders charged with developing a new national strategy for post-secondary education that will meet the needs of Americas diverse population and also address the economic and workforce needs of the country's future
He is the holder of seven technology patents and is a member of numerous technical and science honor societies. He is a Fellow of the Institute for Electrical and Electronics Engineers, a Fellow of the U.K-based Royal Academy of Engineering, a member of the US-based National Academy of Engineering, a Fellow of the American Academy of Arts and Sciences, a member of the Board of Directors for the Bank of New York/Mellon, a member of the Republic of China’s Science and Technology Advisory Group Board (2008-2011), a member of the Board of Trustees at Rensselaer Polytechnic Institute, a member of the Board of Directors of Liberty Mutual, a member of the Board of Directors of AMD, a member of the Board of Directors of the Delphi Company, a member of the Board of Trustees of The MITRE Corporation and a Senior Fellow of the Kauffman Foundation. In 2010, Mr. Donofrio became a member of the U. S. Secretary of Energy’s Advisory Board (SEAB), the Penn State School of International Affairs External Advisory Board and the Workforce Opportunity Services Academic Advisory Board. In 2011, he became a member of the Atlas Research Board of Advisors, Sproxil’s Board of Directors, the Syracuse University Board of Trustees and was named to the Board of Regents for Higher Education by the Governor of Connecticut
Please click here for more information
Terry Fetterhoff
Senior Director, Technology Management
Head, US Chief Technology Office
F. Hoffmann-La Roche Ltd., Diagnostics Division
Terry is Sr Director of Technology Management and Head of the US Chief Technology Office for Roche Diagnostics in which he oversees the identification and evaluation of emerging technologies relevant to the future of clinical diagnostics, and is responsible for global Open Innovation initiatives within Roche Diagnostics. Prior to joining Roche, Terry received a Masters degree in Pathology from University of Western Australia (1981). He then worked at the Denver Children's Hospital from 1982 to 1987 where he oversaw the construction of a 3 laser, 5 parameter flow cytometer. In 1987, Mr. Fetterhoff took the position of R&D Manager for Boehringer Mannheim in Indianapolis in which he was responsible for development and manufacturing of Immunology and Biochemical product lines. He became Director of R&D for Boehringer Mannheim Biochemicals in 1995. During this time, the primary research focus was the development of methods to isolate pancreatic islets for subsequent transplantation into diabetics. When Roche acquired Boehringer Mannheim in 1996, Terry was responsible for moving the R&D function to Berkeley where the focus of the research was in vitro protein expression.
Senior Director, Technology Management
Head, US Chief Technology Office
F. Hoffmann-La Roche Ltd., Diagnostics Division
Terry is Sr Director of Technology Management and Head of the US Chief Technology Office for Roche Diagnostics in which he oversees the identification and evaluation of emerging technologies relevant to the future of clinical diagnostics, and is responsible for global Open Innovation initiatives within Roche Diagnostics. Prior to joining Roche, Terry received a Masters degree in Pathology from University of Western Australia (1981). He then worked at the Denver Children's Hospital from 1982 to 1987 where he oversaw the construction of a 3 laser, 5 parameter flow cytometer. In 1987, Mr. Fetterhoff took the position of R&D Manager for Boehringer Mannheim in Indianapolis in which he was responsible for development and manufacturing of Immunology and Biochemical product lines. He became Director of R&D for Boehringer Mannheim Biochemicals in 1995. During this time, the primary research focus was the development of methods to isolate pancreatic islets for subsequent transplantation into diabetics. When Roche acquired Boehringer Mannheim in 1996, Terry was responsible for moving the R&D function to Berkeley where the focus of the research was in vitro protein expression.
Mary Haak-Frendscho, Ph.D.
Chief Executive Officer and member of the Board of Directors at Igenica, Inc.
Mary Haak-Frendscho, PhD is Chief Executive Officer and member of the Board of Directors at Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of breakthrough antibody-based cancer therapeutics.
Prior to joining Igenica, Dr. Haak-Frendscho established and is currently Chairman of the Board of Compugen, Inc., a subsidiary of Compugen, Ltd., devoted to translating in silico predicted targets into antibody therapeutics. Previously, Dr. Haak-Frendscho was founding President, Chief Scientific Officer and Board member of Takeda San Francisco, establishing and overseeing Takeda’s Center of Excellence for antibody biologics. Prior to Takeda Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led antibody programs. At Genentech, she played a key role in the development of omalizumab (Xolair®).
She has authored over 70 scientific articles and has over 30 issued plus pending patents, primarily related to Abs across multiple therapeutic areas. An immunologist by training, Dr. Haak-Frendscho obtained her BS from the University of Michigan, MLA from Washington University in St. Louis, MS from SUNY-Stony Brook, CSEP from Columbia University Graduate School of Business and PhD from the University of Wisconsin, where she has an adjunct appointment.
Chief Executive Officer and member of the Board of Directors at Igenica, Inc.
Mary Haak-Frendscho, PhD is Chief Executive Officer and member of the Board of Directors at Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of breakthrough antibody-based cancer therapeutics.
Prior to joining Igenica, Dr. Haak-Frendscho established and is currently Chairman of the Board of Compugen, Inc., a subsidiary of Compugen, Ltd., devoted to translating in silico predicted targets into antibody therapeutics. Previously, Dr. Haak-Frendscho was founding President, Chief Scientific Officer and Board member of Takeda San Francisco, establishing and overseeing Takeda’s Center of Excellence for antibody biologics. Prior to Takeda Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led antibody programs. At Genentech, she played a key role in the development of omalizumab (Xolair®).
She has authored over 70 scientific articles and has over 30 issued plus pending patents, primarily related to Abs across multiple therapeutic areas. An immunologist by training, Dr. Haak-Frendscho obtained her BS from the University of Michigan, MLA from Washington University in St. Louis, MS from SUNY-Stony Brook, CSEP from Columbia University Graduate School of Business and PhD from the University of Wisconsin, where she has an adjunct appointment.
Anthony P. Green, Ph.D.
Vice President, Technology Commercialization Group: Life Sciences for Ben Franklin Technology Partners of Southeastern PA (BFTP/SEP) and Ben Franklin Director of The Nanotechnology Institute™ (NTI) and Energy Commercialization Institute. He is also a Visiting Research Professor, School of Biomedical Engineering, Drexel University.
At BFTP/SEP, Dr. Green is focused on Ben Franklin's larger and region-wide technology partnerships and major initiatives, including the NTI and the Energy Commercialization Institute (ECI). He is also focused on new and evolving life sciences initiatives, university/industry partnerships in advanced textiles and water and the development and implementation new commercialization models. He is Chair of the Innovation Partnership Program, and a member of the Board of Visitors of the University of the Sciences Misher College of Arts and Sciences and the PA Life Science Leadership Advisory Council. Dr. Green has over 30 years experience in the biotechnology industry focusing on diagnostics and gene transfer technologies. In addition to his work with BectonDickinson and Migliara/Kaplan Associates, Dr. Green track record includes research, development and commercialization of cutting-edge technologies primarily through small, emerging companies, including Centocor and Puresyn. Dr. Green earned his Bachelor of Science degree in Immunology, with Honors, from Brown University, in Providence, Rhode Island and his Ph.D. from Temple University School of Medicine, in Microbiology and Immunology.
Vice President, Technology Commercialization Group: Life Sciences for Ben Franklin Technology Partners of Southeastern PA (BFTP/SEP) and Ben Franklin Director of The Nanotechnology Institute™ (NTI) and Energy Commercialization Institute. He is also a Visiting Research Professor, School of Biomedical Engineering, Drexel University.
At BFTP/SEP, Dr. Green is focused on Ben Franklin's larger and region-wide technology partnerships and major initiatives, including the NTI and the Energy Commercialization Institute (ECI). He is also focused on new and evolving life sciences initiatives, university/industry partnerships in advanced textiles and water and the development and implementation new commercialization models. He is Chair of the Innovation Partnership Program, and a member of the Board of Visitors of the University of the Sciences Misher College of Arts and Sciences and the PA Life Science Leadership Advisory Council. Dr. Green has over 30 years experience in the biotechnology industry focusing on diagnostics and gene transfer technologies. In addition to his work with BectonDickinson and Migliara/Kaplan Associates, Dr. Green track record includes research, development and commercialization of cutting-edge technologies primarily through small, emerging companies, including Centocor and Puresyn. Dr. Green earned his Bachelor of Science degree in Immunology, with Honors, from Brown University, in Providence, Rhode Island and his Ph.D. from Temple University School of Medicine, in Microbiology and Immunology.
Eric Hale, J.D, M.S, MBA
Associate Director
Office of Clinical and Preclinical Development Partnerships, Center for Cancer Research, National Cancer Institute
Eric Hale is an Associate Director in the Office of the Director, Center for Cancer Research where he is responsible for providing review and approval of the Center’s technology transfer portfolio as well as serving as an advisor to the Director and technical liaison on issues relating to legal, ethics, scientific administration and technology development.
He holds a Doctorate Degree in Law and Masters in Biochemistry from University of Maryland. He received a Master’s degree in business administration from the Johns Hopkins University and an undergraduate degree in chemistry. With degrees in law, chemistry, biochemistry, and business, Eric Hale has enjoyed and been able to meet the challenges posed by his past positions in government, biotech, academia, pharmaceutical, and regulatory affairs.
Associate Director
Office of Clinical and Preclinical Development Partnerships, Center for Cancer Research, National Cancer Institute
Eric Hale is an Associate Director in the Office of the Director, Center for Cancer Research where he is responsible for providing review and approval of the Center’s technology transfer portfolio as well as serving as an advisor to the Director and technical liaison on issues relating to legal, ethics, scientific administration and technology development.
He holds a Doctorate Degree in Law and Masters in Biochemistry from University of Maryland. He received a Master’s degree in business administration from the Johns Hopkins University and an undergraduate degree in chemistry. With degrees in law, chemistry, biochemistry, and business, Eric Hale has enjoyed and been able to meet the challenges posed by his past positions in government, biotech, academia, pharmaceutical, and regulatory affairs.
John D. Hewes, Ph.D.
Technology Transfer Specialist ,Technology Marketing Group, Technology Transfer Center, National Cancer Institute
Dr. Hewes has post-graduate degrees in chemistry and technology management. Following post-doctoral fellowships in France and Germany, Dr. Hewes was employed at AlliedSignal, Inc. as a Research Chemist and Business Unit Liaison. Then, in a stint as a Program Manager with the National Institute of Standards and Technology’s Advanced Technology Program, Dr. Hewes implemented intramural and extramural funding programs for high-throughput screening for advanced materials. Dr. Hewes then served as the Director for Government and University Relations at Honeywell International Specialty Materials, where he identified and nurtured cross-Corporate opportunities as the technical liaison to several government agencies. Dr. Hewes joined the National Cancer Institute Technology Transfer Center in 2007, where his principal role is assisting in identifying translational research opportunities for the Intramural Research Program scientists.
Technology Transfer Specialist ,Technology Marketing Group, Technology Transfer Center, National Cancer Institute
Dr. Hewes has post-graduate degrees in chemistry and technology management. Following post-doctoral fellowships in France and Germany, Dr. Hewes was employed at AlliedSignal, Inc. as a Research Chemist and Business Unit Liaison. Then, in a stint as a Program Manager with the National Institute of Standards and Technology’s Advanced Technology Program, Dr. Hewes implemented intramural and extramural funding programs for high-throughput screening for advanced materials. Dr. Hewes then served as the Director for Government and University Relations at Honeywell International Specialty Materials, where he identified and nurtured cross-Corporate opportunities as the technical liaison to several government agencies. Dr. Hewes joined the National Cancer Institute Technology Transfer Center in 2007, where his principal role is assisting in identifying translational research opportunities for the Intramural Research Program scientists.
Michael King Jolly, Pharm.D.
Senior Vice President, Quintiles Innovation
Michael King Jolly, Pharm.D., is Senior Vice President of Quintiles Innovation, where he leads initiatives to develop statistical and operational methodologies, translational Research and Development, and electronic medical record-enabled applications to speed drug development, reduce cost, and improve outcomes success.
Dr. Jolly’s pharmaceutical career began at Burroughs Wellcome Co. in 1983. While at Burroughs Wellcome, he served as Project Leader for more than five new molecular entities in cardiovascular medicine, Section Head for Cardiovascular Medicine, and Brand Leader for LANOXIN brand digoxin for heart failure.
Dr. Jolly first joined Quintiles in 1995 and led a strategic business unit that provided oversight of more than 40 cardiovascular product development programs ranging from pre-IND to Phase IV. In 2000, he took a position at King Pharmaceuticals as Executive Vice President of Research and Development, where he formed a multidisciplinary research and development organization using a “virtual development model” in which outsourced partners performed all operations work, directed by a small core of functional experts. In early 2007, Dr. Jolly returned to Quintiles and subsequently formed the Innovation Business Unit.
Dr. Jolly also teaches at Duke University Medical School and the School of Pharmacy at University of North Carolina at Chapel Hill. He has authored eight NDAs and three sNDAs during his career.
Dr. Jolly received his undergraduate degree from the University of North Carolina at Chapel Hill, and a Doctor of Pharmacy from the University of Texas at San Antonio. He subsequently completed a fellowship in clinical drug research and drug development from University of North Carolina at Chapel Hill and Burroughs Wellcome Co. Dr. Jolly is also a graduate of the Burroughs Wellcome Management Institute
Senior Vice President, Quintiles Innovation
Michael King Jolly, Pharm.D., is Senior Vice President of Quintiles Innovation, where he leads initiatives to develop statistical and operational methodologies, translational Research and Development, and electronic medical record-enabled applications to speed drug development, reduce cost, and improve outcomes success.
Dr. Jolly’s pharmaceutical career began at Burroughs Wellcome Co. in 1983. While at Burroughs Wellcome, he served as Project Leader for more than five new molecular entities in cardiovascular medicine, Section Head for Cardiovascular Medicine, and Brand Leader for LANOXIN brand digoxin for heart failure.
Dr. Jolly first joined Quintiles in 1995 and led a strategic business unit that provided oversight of more than 40 cardiovascular product development programs ranging from pre-IND to Phase IV. In 2000, he took a position at King Pharmaceuticals as Executive Vice President of Research and Development, where he formed a multidisciplinary research and development organization using a “virtual development model” in which outsourced partners performed all operations work, directed by a small core of functional experts. In early 2007, Dr. Jolly returned to Quintiles and subsequently formed the Innovation Business Unit.
Dr. Jolly also teaches at Duke University Medical School and the School of Pharmacy at University of North Carolina at Chapel Hill. He has authored eight NDAs and three sNDAs during his career.
Dr. Jolly received his undergraduate degree from the University of North Carolina at Chapel Hill, and a Doctor of Pharmacy from the University of Texas at San Antonio. He subsequently completed a fellowship in clinical drug research and drug development from University of North Carolina at Chapel Hill and Burroughs Wellcome Co. Dr. Jolly is also a graduate of the Burroughs Wellcome Management Institute
Carol Nacy
Founder and Chief Executive Officer, Sequella, Inc.
Dr. Carol A. Nacy is currently founder and Chief Executive Officer of Sequella, Inc., a fifteen year- old privately-held pharmaceutical company that commercializes new and more effective treatments for life-threatening infectious diseases. Sequella has a novel antibiotic in a pivotal trial in Russia for MDR-TB with its corporate partner Infectex, a Phase 2 efficacy study in Africa in drug-sensitive TB, and a Phase 2 efficacy study in Texas for Helicobacter pylori infections. Sequella also has an extensive pipeline of earlier-stage drugs moving to the clinic in various infectious disease indications. Sequella has ongoing research collaborations with large pharmaceutical companies and academic centers for development of new drugs for neglected diseases. Sequella raised $81M to date from institutional and individual investors and peer- reviewed grants.
Prior to Sequella, Dr. Nacy was Executive Vice President and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 to establish Sequella, Inc. and was part-time Chief Scientific Officer (1997-1998) for Anergen, Inc., a California company focused on autoimmune diseases. There, she reorganized the scientific staff and positioned the company for acquisition by Corixa Corp. in December 1998.
Dr. Nacy became full time CEO and Chair of the Board of Sequella in January 1999. She is a member of the Board of Directors of for-profit companies (Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Tech Council of Maryland, Foundation for Soldier and World Health, among others) and on a number of committees in global health organizations. Prior to her business experience, Dr. Nacy was career scientist and science manager for 17 years at the Walter Reed Army Institute of Research in Washington, DC, where she studied tropical infectious diseases. She has published over 160 scientific papers to date.
Dr. Nacy was elected to the American Academy of Microbiology in 1985. She maintains strong ties to the scientific research community, was President of the American Society for Microbiology (1996) and the Society for Leukocyte Biology (1993), and was on the Board of the National Academy of Science, National Research Council (1996-2001). She is an adjunct faculty member of both the Department of Biology at the Catholic University of America, and the Department of Tropical Diseases at the George Washington University, Washington, DC. She earned her A.B., M.S., and Ph.D. degrees from the Catholic University of America in Washington, DC: in 2002 she was awarded a Lifetime Achievement Award in Science from this institution.
Dr. Nacy was singled out as a Top 50 Innovator in the U.S. by Inc. Magazine in 2002, named Entrepreneur of the Year by Women in BIO in 2004, the state of Maryland named her in its Top 100 Business Women in 2005, and the Washington Business Journal named her as a top 25 female executive in the Washington DC metropolitan area in 2005. In 2006, she received a National Leadership Award in Healthcare from the National Urban Technology Center in New York City, and in 2007 she was honored with a Special Outstanding Achievement Award for Clinical Trials by Women in BIO. In December 2009 she was awarded the Humanitarian Award, Hope is a Vaccine, by the Global Alliance for Immunization against Aids (GAIA) for her work to create new drugs for TB.
Dr. Nacy is married to Monte S. Meltzer, M.D., has 5 children and 5 grandchildren, and lives in Washington, DC
Founder and Chief Executive Officer, Sequella, Inc.
Dr. Carol A. Nacy is currently founder and Chief Executive Officer of Sequella, Inc., a fifteen year- old privately-held pharmaceutical company that commercializes new and more effective treatments for life-threatening infectious diseases. Sequella has a novel antibiotic in a pivotal trial in Russia for MDR-TB with its corporate partner Infectex, a Phase 2 efficacy study in Africa in drug-sensitive TB, and a Phase 2 efficacy study in Texas for Helicobacter pylori infections. Sequella also has an extensive pipeline of earlier-stage drugs moving to the clinic in various infectious disease indications. Sequella has ongoing research collaborations with large pharmaceutical companies and academic centers for development of new drugs for neglected diseases. Sequella raised $81M to date from institutional and individual investors and peer- reviewed grants.
Prior to Sequella, Dr. Nacy was Executive Vice President and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 to establish Sequella, Inc. and was part-time Chief Scientific Officer (1997-1998) for Anergen, Inc., a California company focused on autoimmune diseases. There, she reorganized the scientific staff and positioned the company for acquisition by Corixa Corp. in December 1998.
Dr. Nacy became full time CEO and Chair of the Board of Sequella in January 1999. She is a member of the Board of Directors of for-profit companies (Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Tech Council of Maryland, Foundation for Soldier and World Health, among others) and on a number of committees in global health organizations. Prior to her business experience, Dr. Nacy was career scientist and science manager for 17 years at the Walter Reed Army Institute of Research in Washington, DC, where she studied tropical infectious diseases. She has published over 160 scientific papers to date.
Dr. Nacy was elected to the American Academy of Microbiology in 1985. She maintains strong ties to the scientific research community, was President of the American Society for Microbiology (1996) and the Society for Leukocyte Biology (1993), and was on the Board of the National Academy of Science, National Research Council (1996-2001). She is an adjunct faculty member of both the Department of Biology at the Catholic University of America, and the Department of Tropical Diseases at the George Washington University, Washington, DC. She earned her A.B., M.S., and Ph.D. degrees from the Catholic University of America in Washington, DC: in 2002 she was awarded a Lifetime Achievement Award in Science from this institution.
Dr. Nacy was singled out as a Top 50 Innovator in the U.S. by Inc. Magazine in 2002, named Entrepreneur of the Year by Women in BIO in 2004, the state of Maryland named her in its Top 100 Business Women in 2005, and the Washington Business Journal named her as a top 25 female executive in the Washington DC metropolitan area in 2005. In 2006, she received a National Leadership Award in Healthcare from the National Urban Technology Center in New York City, and in 2007 she was honored with a Special Outstanding Achievement Award for Clinical Trials by Women in BIO. In December 2009 she was awarded the Humanitarian Award, Hope is a Vaccine, by the Global Alliance for Immunization against Aids (GAIA) for her work to create new drugs for TB.
Dr. Nacy is married to Monte S. Meltzer, M.D., has 5 children and 5 grandchildren, and lives in Washington, DC
Christine K. Norton
Co-Founder, Minnesota Breast Cancer Coalition
Christine Norton is a retired teacher, a 23 year breast cancer survivor, co-founder of the Minnesota Breast Cancer Coalition, and a National Breast Cancer Coalition Board member. Christine has done peer-reviews for the DoD Breast Cancer Research Program, NCI, the Avon Foundation, and the University of Minnesota. A former member of the Scientific Advisory Board of the Avon Foundation, Christine is currently a public member of the MN Board of Nursing, and serves on the MN Community Measurement Board, and the Piper Breast Center Advisory Board. She is also a reviewer for HealthNewsReview.org
Co-Founder, Minnesota Breast Cancer Coalition
Christine Norton is a retired teacher, a 23 year breast cancer survivor, co-founder of the Minnesota Breast Cancer Coalition, and a National Breast Cancer Coalition Board member. Christine has done peer-reviews for the DoD Breast Cancer Research Program, NCI, the Avon Foundation, and the University of Minnesota. A former member of the Scientific Advisory Board of the Avon Foundation, Christine is currently a public member of the MN Board of Nursing, and serves on the MN Community Measurement Board, and the Piper Breast Center Advisory Board. She is also a reviewer for HealthNewsReview.org
Gil Price, M.D.
Chief Executive Officer, MaGil IRB, Inc.
Chief Executive Officer, Drug Safety Solutions
Dr. Gil Price is a clinical physician trained in Internal Medicine with a long-standing interest in the study of adverse drug reactions, drug utilization, drug development and regulation. He is an accomplished senior level manager with over 26 years of diverse therapeutic drug development experience. His responsibilities have included pharmacovigilance, competitive intelligence, and clinical development
Gil has launched three companies: a biotech firm which exited within 15 months at a 23x multiple; Drug Safety Solutions, a pharmacoviligance consulting firm and Ma Gil, a firm provided preferred IRB services to the Life Sciences industry
Prior to his current position as Founder and CEO of Drug Safety Solutions, Dr. Price was the Director of Clinical Development for Oncology at MedImmune Inc. He previously worked in the CRO sector at ClinTrials. Dr. Price began his pharmaceutical career at Glaxo, Inc. in Research Triangle Park, NC, where he worked for nearly nine years on both the commercial and research sides of the company
Dr. Price is a member of the American Medical Association, the Academy of Pharmaceutical Physicians, the American Society of Microbiology, the Association of Clinical Research Professionals, and the Drug Information Association
Chief Executive Officer, MaGil IRB, Inc.
Chief Executive Officer, Drug Safety Solutions
Dr. Gil Price is a clinical physician trained in Internal Medicine with a long-standing interest in the study of adverse drug reactions, drug utilization, drug development and regulation. He is an accomplished senior level manager with over 26 years of diverse therapeutic drug development experience. His responsibilities have included pharmacovigilance, competitive intelligence, and clinical development
Gil has launched three companies: a biotech firm which exited within 15 months at a 23x multiple; Drug Safety Solutions, a pharmacoviligance consulting firm and Ma Gil, a firm provided preferred IRB services to the Life Sciences industry
Prior to his current position as Founder and CEO of Drug Safety Solutions, Dr. Price was the Director of Clinical Development for Oncology at MedImmune Inc. He previously worked in the CRO sector at ClinTrials. Dr. Price began his pharmaceutical career at Glaxo, Inc. in Research Triangle Park, NC, where he worked for nearly nine years on both the commercial and research sides of the company
Dr. Price is a member of the American Medical Association, the Academy of Pharmaceutical Physicians, the American Society of Microbiology, the Association of Clinical Research Professionals, and the Drug Information Association
George F. Tidmarsh, M.D., Ph.D.
President, Chief Executive Officer and Secretary, La Jolla Pharmaceutical Co.
Dr. Tidmarsh’s 22 years of experience in biotechnology include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla in January 2012, Dr. Tidmarsh served as the Chief Executive Officer of Solana Therapeutics, Inc.
Previously, he served as the Chief Executive Officer of Horizon Pharma, Inc. (NASDAQ: HZNP), a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of conditions such as osteoarthritis and rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) and held senior positions at Coulter Pharmaceutical, Inc. [acquired by GlaxoSmithKline (NYSE: GSK)] and SEQUUS Pharmaceuticals, Inc. [acquired by Johnson & Johnson (NYSE: JNJ)]. While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents
Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and remains a Consulting Professor of Pediatrics and Neonatology
President, Chief Executive Officer and Secretary, La Jolla Pharmaceutical Co.
Dr. Tidmarsh’s 22 years of experience in biotechnology include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla in January 2012, Dr. Tidmarsh served as the Chief Executive Officer of Solana Therapeutics, Inc.
Previously, he served as the Chief Executive Officer of Horizon Pharma, Inc. (NASDAQ: HZNP), a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of conditions such as osteoarthritis and rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) and held senior positions at Coulter Pharmaceutical, Inc. [acquired by GlaxoSmithKline (NYSE: GSK)] and SEQUUS Pharmaceuticals, Inc. [acquired by Johnson & Johnson (NYSE: JNJ)]. While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents
Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and remains a Consulting Professor of Pediatrics and Neonatology